Amylyx Pharmaceuticals (AMLX) Institutional Ownership

During the previous two years, 145 institutional investors and hedge funds held shares of Amylyx Pharmaceuticals. The most heavily invested institutionals were Pictet Asset Management SA ($42.07M), Stonepine Capital Management LLC ($36.80M), Rock Springs Capital Management LP ($33.32M), Adage Capital Partners GP L.L.C. ($31.13M), Perceptive Advisors LLC ($27.51M), Great Point Partners LLC ($20.90M), and Franklin Resources Inc. ($19.50M).Learn more on AMLX's institutional investors.

95.84% of Amylyx Pharmaceuticals stock is owned by institutional investors. Learn more on AMLX's institutional investor holdings.

Of the 119 institutional investors that purchased Amylyx Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: AQR Capital Management LLC ($3.22M), abrdn plc ($2.05M), Almitas Capital LLC ($1.95M), Boxer Capital Management LLC ($1.75M), Bank of America Corp DE ($1.51M), Stonepine Capital Management LLC ($1.39M), and Acadian Asset Management LLC ($1.21M).

Institutional investors have bought a total of 30,599,720 shares in the last 24 months. This purchase volume represents approximately $287.93M in transactions.

Of the 55 institutional investors that sold Amylyx Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Perceptive Advisors LLC ($1.98M), Avidity Partners Management LP ($1.69M), Federated Hermes Inc. ($1.43M), Alyeska Investment Group L.P. ($1.20M), Millennium Management LLC ($976.28K), Allspring Global Investments Holdings LLC ($524.60K), and Alpha Wave Global LP ($520.86K).

Institutional investors have sold a total of 12,015,456 shares in the last 24 months. This volume of shares sold represents approximately $138.75M in transactions.